|
1
|
White NM and Yousef GM: MicroRNAs:
exploring a new dimension in the pathogenesis of kidney cancer. BMC
Med. 8:652010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Spronsen DJ, de Weijer KJ, Mulders PF
and De Mulder PH: Novel treatment strategies in clear-cell
metastatic renal cell carcinoma. Anticancer Drugs. 16:709–717.
2005.PubMed/NCBI
|
|
3
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN,
Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of
FoxM1 is associated with tumor progression in patients with clear
cell renal cell carcinoma. J Transl Med. 10:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan BC, Mackinnon AC and Al-Ahmadie HA:
Recent developments in the pathology of renal tumors: morphology
and molecular characteristics of select entities. Arch Pathol Lab
Med. 133:1026–1032. 2009.PubMed/NCBI
|
|
6
|
Cindolo L, Patard JJ, Chiodini P, Schips
L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B,
Zigeuner RE, et al: Comparison of predictive accuracy of four
prognostic models for nonmetastatic renal cell carcinoma after
nephrectomy: a multicenter European study. Cancer. 104:1362–1371.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
8
|
Zisman A, Pantuck AJ, Wieder J, Chao DH,
Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk
group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell
carcinoma. J Clin Oncol. 20:4559–4566. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
10
|
Pampalakis G, Diamandis EP, Katsaros D and
Sotiropoulou G: Down-regulation of dicer expression in ovarian
cancer tissues. Clin Biochem. 43:324–327. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garzon R, Pichiorri F, Palumbo T,
Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder
H, et al: MicroRNA gene expression during retinoic acid-induced
differentiation of human acute promyelocytic leukemia. Oncogene.
26:4148–4157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schickel R, Boyerinas B, Park SM and Peter
ME: MicroRNAs: key players in the immune system, differentiation,
tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
14
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zaman MS, Shahryari V, Deng G, Thamminana
S, Saini S, Majid S, Chang I, Hirata H, Ueno K, Yamamura S, et al:
Up-regulation of microRNA-21 correlates with lower kidney cancer
survival. PLoS One. 7:e310602012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
|
17
|
Kawakami K, Enokida H, Chiyomaru T,
Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama
K, Nohata N, et al: The functional significance of miR-1 and
miR-133a in renal cell carcinoma. Eur J Cancer. 48:827–836. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruebel K, Leontovich AA, Stilling GA,
Zhang S, Righi A, Jin L and Lloyd RV: MicroRNA expression in ileal
carcinoid tumors: downregulation of microRNA-133a with tumor
progression. Mod Pathol. 23:367–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rao PK, Missiaglia E, Shields L, Hyde G,
Yuan B, Shepherd CJ, Shipley J and Lodish HF: Distinct roles for
miR-1 and miR-133a in the proliferation and differentiation of
rhabdomyosarcoma cells. FASEB J. 24:3427–3437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patron JP, Fendler A, Bild M, Jung U,
Müller H, Arntzen MØ, Piso C, Stephan C, Thiede B, Mollenkopf HJ,
et al: MiR-133b targets antiapoptotic genes and enhances death
receptor-induced apoptosis. PLoS One. 7:e353452012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uchida Y, Chiyomaru T, Enokida H, Kawakami
K, Tatarano S, Kawahara K, Nishiyama K, Seki N and Nakagawa M:
MiR-133a induces apoptosis through direct regulation of GSTP1 in
bladder cancer cell lines. Urol Oncol. 31:115–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiyomaru T, Enokida H, Kawakami K,
Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa
M: Functional role of LASP1 in cell viability and its regulation by
microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119.
2001.PubMed/NCBI
|
|
26
|
Morgia G, Falsaperla M, Malaponte G,
Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix
metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2,
MMP9) markers of prostate cancer. Urol Res. 33:44–50. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moses MA, Wiederschain D, Loughlin KR,
Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix
metalloproteinases in urine of cancer patients. Cancer Res.
58:1395–1399. 1998.PubMed/NCBI
|
|
28
|
Brown PD and Giavazzi R: Matrix
metalloproteinase inhibition: a review of anti-tumour activity. Ann
Oncol. 6:967–974. 1995.PubMed/NCBI
|
|
29
|
Hong S, Park KK, Magae J, Ando K, Lee TS,
Kwon TK, Kwak JY, Kim CH and Chang YC: Ascochlorin inhibits matrix
metalloproteinase-9 expression by suppressing activator
protein-1-mediated gene expression through the ERK1/2 signaling
pathway: inhibitory effects of ascochlorin on the invasion of renal
carcinoma cells. J Biol Chem. 280:25202–25209. 2005. View Article : Google Scholar
|
|
30
|
Tsai JP, Liou JH, Kao WT, Wang SC, Lian JD
and Chang HR: Increased expression of intranuclear matrix
metalloproteinase 9 in atrophic renal tubules is associated with
renal fibrosis. PLoS One. 7:e481642012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Legallicier B, Trugnan G, Murphy G,
Lelongt B and Ronco P: Expression of the type IV collagenase system
during mouse kidney development and tubule segmentation. J Am Soc
Nephrol. 12:2358–2369. 2001.PubMed/NCBI
|
|
32
|
Ogbureke KU and Fisher LW: Renal
expression of SIBLING proteins and their partner matrix
metalloproteinases (MMPs). Kidney Int. 68:155–166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Catania JM, Chen G and Parrish AR: Role of
matrix metalloproteinases in renal pathophysiologies. Am J Physiol
Renal Physiol. 292:F905–F911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stetler-Stevenson WG, Hewitt R and
Corcoran M: Matrix metalloproteinases and tumor invasion: from
correlation and causality to the clinic. Semin Cancer Biol.
7:147–154. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zucker S, Lysik RM, Zarrabi MH and Moll U:
M(r) 92,000 type IV collagenase is increased in plasma of patients
with colon cancer and breast cancer. Cancer Res. 53:140–146.
1993.PubMed/NCBI
|
|
37
|
Lakka SS, Gondi CS, Yanamandra N, Dinh DH,
Olivero WC, Gujrati M and Rao JS: Synergistic down-regulation of
urokinase plasminogen activator receptor and matrix
metalloproteinase-9 in SNB19 glioblastoma cells efficiently
inhibits glioma cell invasion, angiogenesis, and tumor growth.
Cancer Res. 63:2454–2461. 2003.
|
|
38
|
Kugler A, Hemmerlein B, Thelen P,
Kallerhoff M, Radzun HJ and Ringert RH: Expression of
metalloproteinase 2 and 9 and their inhibitors in renal cell
carcinoma. J Urol. 160:1914–1918. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lein M, Jung K, Laube C, Hübner T,
Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and
Loening SA: Matrix-metalloproteinases and their inhibitors in
plasma and tumor tissue of patients with renal cell carcinoma. Int
J Cancer. 85:801–804. 2000. View Article : Google Scholar : PubMed/NCBI
|
